Company

DEMAND FOR GENE EXPRESSION SERVICES NOW MET BY NEW SERVICE LABS AT MICROARRAYS INC

MI offers both standard and highly customized microarray laboratory services for a large variety of human, animal, plant and micro organisms

March 22, 2012 Huntsville, AL (PRWEB) MI has parlayed their extensive expertise in all aspects of gene expression science to meet the demand for custom laboratory services for both large and small gene expression projects. Available across a range of diagnostic, drug development and life sciences applications, the MI Services Lab offers the widest availability of microarrays for human and model systems, including rat and mouse.

Immediately available, the newly expanded services labs handle a variety of microarray platforms to meet researchers needs including arrays from Affymetrix, Illumina, and others. MI’s own highly sensitive MI ReadyArrays™ and MI PathArrays™ are available as standard products or in highly customized formats for services projects too, allowing for a combination of whole genome or targeted gene expression profiles that include specific biomarkers for a client’s particular areas of interest.

Announcing the launch of these new services, Joel Peek, President and CEO of MI stated, "The customized laboratory services that we've provided on a select project basis will now be made available to everyone. Regardless of the size of their project, our services facility will enable researchers to take full advantage of the extensive microarray expertise that MI has developed over the past 12 years. We're excited by this new offering and look forward to assisting researchers with their array projects."

About MI

MI is an emerging leader in molecular diagnostics and analysis of DNA and proteins. MI's innovations in array-based technologies have been applied in analyte testing, diagnostics, identification of viral and bacterial pathogens, and personalized medicine.

Diatherix Laboratories and Microarrays Inc. form Strategic Partnership

New alliance to bring more sensitive and accurate clinical tests into physicians' arsenal for detecting infectious diseasesl

March 22, 2012 Huntsville, AL (PRWEB) Diatherix Laboratories and Microarrays Inc. (MI) jointly announce they have entered a strategic partnership to develop industry leading infectious disease diagnostic assays.

The ever-increasing prevalence of infectious and drug-resistant organisms requires that diagnostic platforms be highly adaptable and progressively more comprehensive.

With this partnership the companies will integrate their proprietary technologies to develop and continually update diagnostic assays, which will achieve the maximum flexibility necessary to better serve the healthcare community.

"This collaboration brings together all of the necessary modalities of discovery, development and implementation for dynamic state of the art diagnostic assays," said Joel Peek, Ph.D., MI's chief executive officer. Diatherix's chief executive officer, Dennis Grimaud, added that "the combination of Diatherix's unique diagnostic identification technology combined with MI's extremely sensitive detection platform will not only assist physicians in accurate testing results for infectious disease, but will also assist in lowering the overall cost of diagnostic testing".

About Diatherix

Diatherix Laboratories, Inc. is a CLIA certified high complexity reference laboratory providing infectious disease diagnostics. Diatherix's innovative testing technology can diagnose a wide variety of infectious diseases faster and more accurately than traditional testing. Their unique analysis platform has been proven to result in better patient outcomes and significant hospital savings.

About MI

MI is an emerging leader in molecular diagnostics and analysis of DNA and proteins. MI's innovations in array-based technologies have been applied in analyte testing, diagnostics, identification of viral and bacterial pathogens, and personalized medicine.

Newly Independent, Microarrays Inc. Sets Sights on Molecular Diagnostics Market

October 11, 2011 (BioArray NEWS, by Justine Petrone) Microarrays Inc. Microarrays Inc. will later this month launch focused microarrays for studying gene pathways related to growth factors, inflammation, and apoptosis. The pending launch is part of a larger decision by the Huntsville, Ala.-based firm to expand beyond selling whole-genome arrays to offering a menu of catalog focused chips.

CEO Joel Peek said that MI could ultimately offer between 20 and 25 such arrays, which it calls PathArrays. Next quarter, for instance, the firm will begin selling arrays for studying transcription factors, cancer, and protein kinases.

"Our goal is to release three additional pathway-specific arrays every quarter," said Peek. He said that the selection of each research-specific area is being driven by interactions between MI and researchers. "Presently, our third pathway-specific selection is near finalization and we've begun evaluating the fourth-wave candidates," Peek said. "However, we anticipate flux in the selection process as word gets out about the tools line and we hear from more interested researchers."Read more >>

Microarrays Inc Introduces MI PathArray Assays for Apoptosis, Growth Factors, and Inflammation

Specific Research Interests are the Focus of New Discovery Tool

HUNTSVILLE, AL, October 19, 2011 (PRWEB) Microarrays Inc (MI) launches its new MI PathArray assays for studying targeted biological pathways. These pathway-centric arrays provide the highest microarray sensitivity in the form of more sharply focused research-specialty arrays, in a multi-assay format. The MI PathArray assays bring a fresh research tool to laboratories involved in the exploration of biological pathways.

MI PathArray assays are ready for immediate shipment for three popular areas of research: Apoptosis, Growth Factors, and Inflammation. MI will quickly expand the MI PathArray products by launching multiple new arrays each quarter. Once complete the MI PathArray product line will include arrays, kits, and hardware for sample preparation, processing, and array hybridization.

Joining the trend toward interactive research development among research tool developers and scientists, MI has initiated a social media campaign using Facebook. Researchers are invited to list their suggestions for upcoming MI PathArray assay development, the evolution of current MI PathArray content and also to participate as a beta testing laboratory.

During the announcement of the release of the new MI PathArray product, company President Joel Peek commented, “MI PathArray assays enable researchers to rapidly spotlight the pertinent targets of their chosen system. With focused and simplified analysis, in conjunction with a multi-assay format, these arrays will help to speed discovery while reducing costs and sample usage. MI has designed these products to strike the right balance between overall target content, cost per assay, and ease of use when compared to traditional whole genome arrays or some of the qPCR formats which can be lacking in content. Moreover, the content of these arrays will be continually updated with the latest research discoveries to remain cutting-edge tools to enable further discoveries.“

About MI

MI's corporate mission is to advance array-based technologies for biological research, detection and diagnostics. In diligent pursuit of this goal, MI has progressed to the forefront of development and commercialization of microarray and array-based technologies. MI technology innovations have applications in the fields of analyte testing, diagnostics, identification of viral and bacterial pathogens, and personalized medicine.

Founded in 1999, MI has its origins in the Microarray Core facility of the Vanderbilt-Ingram Comprehensive Cancer Center in Nashville, Tennessee. As a result of the growing expertise, proficiency and printing innovations developed at the Cancer Center, MI was established as an autonomous company in November 2000 and has been privately held since May 2010. In May 2008, MI relocated to the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama. This move allowed MI the much needed ability to expand its capacity, as well as foster close relationships in the exciting, growing field of personalized medicine.

Three New Agreements in the European Union Expand Business Opportunities for Microarrays Inc

EU Distributors Now Offer Unique Microarray Inc Capabilities Which Allow the Creation of Research Tools and Diagnostic Tests to Screen for Biological Agents and Other Molecules

HUNTSVILLE, AL, June 9, 2011 (PRWEB) Microarrays Inc (MI) announces distribution agreements, which will facilitate expansion of MI’s commercial activities into the European Union biotechnology markets. Three distributors, Cambio Ltd (UK and Eire; cambio.com), BioCat GmbH (Germany, Austria, and Switzerland; biocat.com), and Biosolutions Ltd. (Greece, Cyprus, and the Balkans; biosolutions.com) will serve as exclusive distributors for MI products and services, including MI’s custom arrays for biological research, detection and diagnostics markets.

Andrew Jennings, President of Business Development stated, "This is an exciting new chapter in our development, we are thrilled to have such high caliber partners representing us in these markets. I believe their knowledge of the local biotechnology landscape coupled to a commitment to excellence will drive our growth in Europe and provide our customers the highest level of service."

About MI

MI's corporate mission is to advance array-based technologies for biological research, detection and diagnostics. In diligent pursuit of this goal, MI has progressed to the forefront of development and commercialization of microarray and array-based technologies. MI technology innovations have applications in the fields of analyte testing, diagnostics, identification of viral and bacterial pathogens, and personalized medicine.

Founded in 1999, MI has its origins in the Microarray Core facility of the Vanderbilt-Ingram Comprehensive Cancer Center in Nashville, Tennessee. As a result of the growing expertise, proficiency and printing innovations developed at the Cancer Center, MI was established as an autonomous company in November 2000 and has been privately held since May 2010. In May 2008, MI relocated to the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama. This move allowed MI the much needed ability to expand its capacity, as well as foster close relationships in the exciting, growing field of personalized medicine.

MI Appoints New President of Business Development to Expand Array Markets Including the Rapidly Developing High-Throughput Arrayed Screening and Diagnostics Sectors

New Microarrays Inc. President of Business Development Andrew Jennings Sees Boundless Growth Opportunities for the Company in Increasing Demand for MI Proprietary Technology Which Enables Moving Traditional Microtiter Plate Assays to High Efficiency Arrays

HUNTSVILLE, AL, February 7, 2011 (PRWEB) Microarrays Inc (MI) today announced the appointment of Andrew Jennings as President of Business Development to lead the expansion of MI's commercial activities. With more than 20 years developing strong sales, marketing and business development organizations for technology companies, Andrew lead the sales organization for Open Biosystems (now Thermo Fisher Scientific) for the last five years. During this time, he spearheaded innovative commercial initiatives to partner with customer organizations, growing significantly ahead of the general biotechnology market and much larger competitors.

"I believe MI's proprietary array techniques and game-changing approach to the manufacture and development of microarray technology empowers our customers to better serve the biological research, detection and diagnostics markets," said Andrew Jennings. "Our early partnerships have allowed MI to mature its products and services, and we will build on this to serve more customers and market segments. I'm excited to be a part of the MI team leading the field in the rapidly developing field of arrayed screening."

About MI

MI's corporate mission is to advance array-based technologies for biological research, detection and diagnostics. In diligent pursuit of this goal, MI has progressed to the forefront of development and commercialization of microarray and array-based technologies. MI technology innovations have applications in the fields of analyte testing, diagnostics, identification of viral and bacterial pathogens, and personalized medicine.

Founded in 1999, MI has its origins in the Microarray Core facility of the Vanderbilt-Ingram Comprehensive Cancer Center in Nashville, Tennessee. As a result of the growing expertise, proficiency and printing innovations developed at the Cancer Center, MI was established as an autonomous company in November 2000 and has been privately held since May 2010. In May 2008, MI relocated to the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama. This move allowed MI the much needed ability to expand its capacity, as well as foster close relationships in the exciting, growing field of personalized medicine.

New MI - Microarrays Inc. Website Showcases Advanced Microarray Capabilities for Research and Diagnostic Assay Applications

Microarrays Inc. Launches Its Newly Designed Website at http://www.microarrays.com Providing a Comprehensive Overview of Their Cutting-Edge Manufacturing Services for Array- based Research and Diagnostic Tools.

HUNTSVILLE, AL, January 20, 2011 (PRWEB) MI, also known as Microarrays Inc, has launched its newly designed website, at http://www.microarrays.com.
The dramatically redesigned site provides potential clients with a comprehensive overview of the cutting-edge manufacturing services for array-based research and diagnostic tools offered by MI.

MI capabilities in the proteomics, assay development and diagnostic markets are prominently featured reflecting the growing demand for new tools for the exciting areas of clinical investigation and research. The new website offers information on refinements to the established MI ReadyArrays for assessing gene expression. Researchers will find detailed information for each of the 40+ organisms offered.

Echoing the excitement of all those involved in the new website's design and construction, Joel Peek, MI President and CEO, commented, "The new web site illustrates many of the capabilities that MI has provided to the research and commercial communities for over a decade now. It provides an enhanced snapshot of the experience and expertise we've developed as a large- scale manufacturing partner and reflects our abilities to respond to client needs, whether they are in the area of product development or diagnostics or healthcare, etc. We're excited to showcase our abilities and look forward to new dialogs and challenges."

About MI

MI's corporate mission is to advance array-based technologies for biological research, detection and diagnostics. In diligent pursuit of this goal, MI has progressed to the forefront of development and commercialization of microarray and array-based technologies. MI technology innovations have applications in the fields of analyte testing, diagnostics, identification of viral and bacterial pathogens, and personalized medicine.

Founded in 1999, MI has its origins in the Microarray Core facility of the Vanderbilt-Ingram Comprehensive Cancer Center in Nashville, Tennessee. As a result of the growing expertise, proficiency and printing innovations developed at the Cancer Center, MI was established as an autonomous company in November 2000 and has been privately held since May 2010. In May 2008, MI relocated to the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama. This move allowed MI the much needed ability to expand its capacity, as well as foster close relationships in the exciting, growing field of personalized medicine.

Newly Independent, Microarrays Inc. Sets Sights on Molecular Diagnostics Market

JULY 20, 2010 (BioArray NEWS, by Justine Petrone) The management Of Microarrays Inc. this week announced that it has purchased the firm from Vanderbilt University, which had owned the company since it founded MI 10 years ago.

The company's managers worked with a group of independent investors to purchase the firm, but did not name the new investors or disclose the sum paid to acquire the company.

According to CEO Joel Peek, MI's change in ownership reflects a shift in its business plans. While it has served as an array foundry for research and diagnostic customers for a decade, it is now seeking to apply its expertise in assay design to the clinical market. Read more >>

Investors buy Vandy biotech Microarrays Inc., set up shop in Huntsville

JULY 19, 2010 (NASHVILLE BUSINESS JOURNAL, by Dan Hieb) - Vanderbilt University has sold a genetic research tool to private investors who intend to speed its development and make its technology available to biotech companies.

Terms of the deal were not disclosed, but Microarrays Inc. CEO Joel Peek said it does not involve any licensing payments to Vanderbilt.

Microarrays Inc. has functioned as its own company since 2000 but moved to Huntsville, Ala., in 2008 to become part of the HudsonAlpha Institute for Biotechnology, a nonprofit research institute that is part of a 150-acre biotech research park. Peek said the research park has provided the company with opportunities to collaborate with like-minded researchers and other new biotechs such as iCubate and Conversant Healthcare Systems.

Economic developers and other leaders in Middle Tennessee have been preaching for years in an orchestrated effort to lure fast-growing biotechnology companies and their high-paying jobs, but the area offers nothing comparable to the 260,000-square-foot facility that was singled out for praise last July by R&D Magazine.

Microarray's technology grew out of techniques developed by the Vanderbilt-Ingram Comprehensive Cancer Center. Researchers developed a way to "print" biological material — called capture probes — onto surfaces such as glass slides. The biological samples can be anything from snippets of genetic material to proteins to other organic compounds. The capture probes are designed to react with the genetic sample being studied, providing a road map that can help detect specific diseases of abnormalities.

As an example, Peek described a future in which a clinician could take a sample from a patient suffering from an upper respiratory illness, use a microarray designed to detect common pathogens, then treat the patient based on the specific disease detected.

"Vanderbilt University has acted as a wonderful steward to our business, fostering both its growth and success," Peek said in a news release. "As MI enters a new era of product development, innovation and commercialization, we felt it was the right time to strike out on our own."